DR. ALICE PRINCE, MD
Medical Practice at Broadway, New York, NY

2007018, Aug 9, 2007

Aug 1, 2006

11/496728

Saul Yedgar - Jerusalem, IL
Alice Prince - Larchmont NY, US

A61K 31/739

514054000

This invention provides for the use of compounds represented by the structure of the general formula (A): wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan; and n is a number from 1 to 1000, wherein any bond between L, Z, Y and X is either an amide or an esteric bond in treating a subject suffering from cystic fibrosis, reducing or delaying the mortality of a subject suffering from cystic fibrosis or ameliorating symptoms associated with cystic fibrosis.

2009017, Jul 9, 2009

Mar 13, 2007

12/282759

Alice Prince - Larchmont NY, US
Liang Tong - Scarsdale NY, US

The Trustees of Columbia University in the City of New York - New York NY

A61K 8/49

424 54

The invention is related to various methods for inhibiting or reducing biofilm formation, treating a biofilm production-related disorder, preventing biofilm formation, and screening for neuraminidase inhibitors. The invention also encompasses a mutant bacterial strain with a deleted neuraminidase gene.

2011011, May 19, 2011

Mar 6, 2009

12/921366

Alice Prince - Larchmont NY, US

A61K 39/395, A61K 31/56, A61K 31/427, A61K 31/4725, A61K 31/496, A61K 31/472, A61K 31/341, A61K 31/713, A61K 38/05, A61K 31/336, A61K 31/192, A61K 31/404, A61K 38/06, A61K 38/16, A61K 38/02, A61K 31/7105, A61P 11/06, A61P 31/00, A61P 11/00, A61P 11/08, A61P 29/00

4241581, 514171, 514365, 514307, 51425301, 514471, 514 44 A, 514 202, 514475, 514570, 514419, 514 17, 514 23

Calpains target junctional components that normally seal the epithelium, forming tight junctions. This selective targeting by calpains facilitates the transmigration of leukocytes across the epithelium and into tissue spaces where they can cause inflammation. The present disclosure provides methods of using calpain inhibitors to prevent epithelial junction reorganization such that leukocyte transmigration is inhibited and accordingly, inflammation reduced or prevented. These methods can at least be used to reduce respiratory inflammation by preventing leukocyte accumulation in pulmonary airways.

2011028, Nov 17, 2011

Nov 13, 2009

13/128688

Alice Prince - Larchmont NY, US
Liang Tong - Scarsdale NY, US

A61K 8/64, A61K 31/7105, C40B 30/02, C07K 2/00, C07K 16/40, A61K 31/4015, A61K 38/08, A01N 43/16, A61K 31/351, A01N 47/44, A61K 31/196, A01N 37/30, A61K 31/215, A61K 31/713, A61K 31/711, A01N 57/16, A61K 39/395, A01N 37/18, A61P 31/04, A01P 1/00, A61K 31/545, A61K 31/43, A61K 31/65, A61K 8/49, A61K 8/60, A61K 8/43, A61K 8/42, A61P 11/00, A61Q 11/00, A01N 43/36

424 49, 514425, 514 44 A, 506 8, 530300, 5303879, 514 24, 514459, 514573, 514529, 4241581, 514 28, 514 26, 514200, 514192, 514152, 514 18

The invention is related to various methods for inhibiting or reducing biofilm formation, treating a biofilm production-related disorder, preventing biofilm formation, and screening for neuraminidase inhibitors.